ANSA Biosciences Holdings Limited

What it is

ANSA Biosciences Holdings Limited is a pharmaceutical and biosciences holding company incorporated in Trinidad and Tobago and listed on the TTSE’s main board under the ticker ASBH. It sits inside the ANSA McAL Group of Companies, headquartered in Port of Spain and one of the largest conglomerates in the Caribbean, whose business operations span eight sectors across the Caribbean and the United States.

The company has two classes of shares in public hands: ordinary shares (ASBH) and 6% cumulative preference shares (ASBH6.00), both quoted on the TTSE. Live market data from the TTSE shows the ordinary shares trading in a range of roughly TTD 1.71 (US$0.25)to TTD 1.90 (US$0.28)(approximately US$0.25–0.28 at the prevailing rate) in recent sessions, with very thin daily volumes that typically print zero trades.

Who owns it

The controlling shareholder is the ANSA McAL Group, itself dominated by the Sabga family of Trinidad and Tobago — one of the most prominent business dynasties in the English-speaking Caribbean. A.

Norman Sabga, LLD (Hon.), holds the position of Executive Chairman of the ANSA McAL Group of Companies. Anthony N.

Sabga III has been Group Chief Executive Officer of ANSA McAL Limited since 2020.

Not published: The exact percentage of ASBH’s share capital held by ANSA McAL, and the corresponding free float available to outside investors, are not disclosed in any TTSE filing or ANSA McAL group annual report reviewed. Trinidad and Tobago’s Securities Act 2012 (Section 63) requires listed companies to file annual reports and material-change disclosures, but subsidiary-level ownership breakdowns are not mandated as standalone exchange filings for holding companies within a group structure.

Who runs it

Not published: ANSA Biosciences Holdings Limited does not maintain a standalone investor-relations page, and the TTSE’s filing archive for ASBH did not yield a board list or management disclosure accessible to this research. The TTSE listing pages for ASBH returned HTTP redirect or access errors on direct retrieval.

At group level, A. Norman Sabga currently serves as Chairman of ANSA Merchant Bank Limited, another listed subsidiary of the group.

It is common practice in the ANSA McAL structure for senior Sabga family members and group executives to hold board seats across subsidiaries, but specific ASBH board appointments could not be verified from available primary sources and are therefore not stated here.

The money, in plain words

Not published: Revenue, net profit, total assets, net margin, return on equity, and price-to-earnings ratio for ANSA Biosciences Holdings Limited as a standalone entity are not available in any primary source retrieved. The TTSE financial-statements page for ASBH returned a redirect error on direct access; the ANSA McAL group’s 2025 audited press release (filed March 2026) covers only the consolidated ANSA McAL group and does not break out ASBH as a separate segment.

The group’s 2024 Annual Report PDF on the TTSE server returned an HTTP 403 (access denied).

What can be stated with confidence from the TTSE live market data: the ordinary shares last traded at TTD 1.50 (≈ US$0.22) to TTD 1.90 (≈ US$0.28) during May–July 2026. A session in June 2026 recorded 600 ordinary shares changing hands at TTD 1.50 (US$0.22)— the kind of daily volume that tells you this is a very thinly traded stock where the price may not fully reflect the underlying business.

The preference shares (ASBH6.00) are quoted at TTD 1.00 (US$0.15)(par) and carry a 6% fixed annual coupon, paid to preference shareholders before ordinary shareholders see anything.

What it is doing now

The broader ANSA McAL group’s 2025 results, filed with the TTSE in March 2026, included a restatement of 2024 comparative figures — partly because valuations of assets acquired in a US acquisition (BleachTech LLC) were finalized in 2025, and partly to reflect operations that were discontinued during 2025. Whether any of those discontinued operations touched the biosciences segment is not specified in the public summary.

The most recent material move specific to ASBH cannot be confirmed from accessible primary filings. Investors monitoring this stock should check the TTSE news feed at stockex.co.tt directly for ASBH-specific regulatory announcements, as the exchange is the primary disclosure channel under the Securities Act 2012.

What to watch

• Financial disclosure: ASBH’s standalone audited accounts — if and when they become accessible on the TTSE or via the company — are the single most important thing a prospective investor needs. Right now, you are buying into the Sabga family’s judgement without being able to check the numbers yourself.
• Group restructuring: ANSA McAL’s 2025 accounts flag discontinued operations; clarity on which subsidiaries were affected, and whether biosciences is being grown or wound down, is essential.
• Liquidity: Ordinary shares trade in single-digit or zero volume on most sessions. Anyone who buys a meaningful position may find it very hard to sell without moving the price.
• Preference-share coverage: The 6% preference coupon ranks ahead of ordinary dividends. Before ordinary shareholders receive anything, the company must be generating enough cash to cover that fixed payment.
• Caribbean healthcare opportunity: Regional pharmaceutical manufacturing remains under-developed; if ASBH is building that capacity under ANSA McAL’s umbrella, the long-run prize could be significant — but the numbers to judge progress are currently not in the public domain.

This is news, not investment advice.